标题
PD-1/PD-L1 inhibitors in haematological malignancies: update 2017
作者
关键词
-
出版物
IMMUNOLOGY
Volume 152, Issue 3, Pages 357-371
出版商
Wiley
发表日期
2017-07-07
DOI
10.1111/imm.12788
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Developing Strategies in the Immunotherapy of Leukemias
- (2017) Jason B. Brayer et al. Cancer Control
- Steroid Refractory Acute Liver GVHD in a Hodgkin's Patient after Allogeneic Stem Transplant Cell Transplantation Following Treatment with Anti PD-1 Antibody, Nivolumab, for Relapsed Disease
- (2016) Shahram Mori et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma
- (2016) H. Miyoshi et al. BLOOD
- Monoclonal antibodies — A new era in the treatment of multiple myeloma
- (2016) Tomas Jelinek et al. BLOOD REVIEWS
- Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
- (2016) Jennifer E. Kim et al. CLINICAL CANCER RESEARCH
- Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas
- (2016) Thomas Menter et al. HUMAN PATHOLOGY
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Immune checkpoint pathways: perspectives on myeloid malignancies
- (2016) Gabriel A. Rivera et al. LEUKEMIA & LYMPHOMA
- Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis
- (2016) Erin A. Marshall et al. Molecular Cancer
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future
- (2016) T. Jelinek et al. OncoImmunology
- Toxicity and management in CAR T-cell therapy
- (2016) Challice L Bonifant et al. Molecular Therapy-Oncolytics
- PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia
- (2015) F. McClanahan et al. BLOOD
- Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
- (2015) J. Kiyasu et al. BLOOD
- Cell of origin of transformed follicular lymphoma
- (2015) R. Kridel et al. BLOOD
- Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
- (2015) G. Gorgun et al. CLINICAL CANCER RESEARCH
- PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
- (2015) B Paiva et al. LEUKEMIA
- Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
- (2015) A Ray et al. LEUKEMIA
- Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
- (2015) C Krupka et al. LEUKEMIA
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
- (2015) Andreas D. Ørskov et al. Oncotarget
- Th17 cells and Tregs : unlikely allies
- (2014) Xin Chen et al. JOURNAL OF LEUKOCYTE BIOLOGY
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells
- (2013) J. H. Myklebust et al. BLOOD
- Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment
- (2013) Holger Krönig et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia
- (2013) D. Brusa et al. HAEMATOLOGICA
- Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
- (2013) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma
- (2013) T. J. Kearl et al. JOURNAL OF IMMUNOLOGY
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- Differential Expression of Programmed Death-1 (PD-1) in Sézary Syndrome and Mycosis Fungoides
- (2012) Fatma Çetinözman et al. ARCHIVES OF DERMATOLOGY
- Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era
- (2012) Philippe Armand et al. BRITISH JOURNAL OF HAEMATOLOGY
- Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State
- (2012) Michele W. L. Teng et al. CANCER RESEARCH
- Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
- (2012) H Tamura et al. LEUKEMIA
- Expression Patterns of the Immunosuppressive Proteins PD-1/CD279 and PD-L1/CD274 at Different Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides
- (2011) Kanchan Kantekure et al. AMERICAN JOURNAL OF DERMATOPATHOLOGY
- Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade
- (2011) William H.D. Hallett et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
- (2011) E. Campo et al. BLOOD
- PD-1/PD-L1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse with Cancer After Allogeneic Stem Cell Transplantation
- (2011) W. J. Norde et al. CANCER RESEARCH
- Expansion of a CD8+PD-1+ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression
- (2011) C. Nunes et al. CLINICAL CANCER RESEARCH
- Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
- (2011) D. J. Andorsky et al. CLINICAL CANCER RESEARCH
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Follicular helper T cells: implications in neoplastic hematopathology
- (2011) Philippe Gaulard et al. SEMINARS IN DIAGNOSTIC PATHOLOGY
- Increased Programmed Death-1 Expression on CD4+ T Cells in Cutaneous T-Cell Lymphoma
- (2010) Sara Samimi et al. ARCHIVES OF DERMATOLOGY
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Interferon- and tumor necrosis factor- induce an immunoinhibitory molecule, B7-H1, via nuclear factor- B activation in blasts in myelodysplastic syndromes
- (2010) A. Kondo et al. BLOOD
- Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells
- (2010) D Eastwood et al. BRITISH JOURNAL OF PHARMACOLOGY
- Clinical significance of B7-H1（PD-L1）expression in human acute leukemia
- (2010) Xiangli Chen et al. CANCER BIOLOGY & THERAPY
- In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors
- (2010) Céline Berthon et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade
- (2010) Jeffrey Weber SEMINARS IN ONCOLOGY
- PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
- (2009) L. Zhang et al. BLOOD
- Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival
- (2009) Simone Muenst et al. HUMAN PATHOLOGY
- PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
- (2008) R. Yamamoto et al. BLOOD
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- (2008) R. Berger et al. CLINICAL CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started